| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Phase 3 | Albireo, an Ipsen Company | <1 mi |
| Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Phase 1 | PharmaIN | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | <1 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | <1 mi |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | <1 mi |
| Sample Collection for Ongoing Research and Product Evaluation Study | — | Natera, Inc. | <1 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | <1 mi |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | Phase 2 | Anwaar Saeed | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| IDOV-Immune for Advanced Solid Tumors | Phase 1 | ViroMissile, Inc. | <1 mi |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | — | Fresenius Kabi | <1 mi |
| Evaluation of Non-Invasive Tests for Metabolic Liver Disease | — | Foundation for the National Institutes of Health | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Phase 1 | GigaGen, Inc. | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function | Phase 1 | Eli Lilly and Company | <1 mi |
| Quantifying Hepatic Mitochondrial Fluxes in Humans | Phase 4 | The University of Texas Health Science Center at San Antonio | <1 mi |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | <1 mi |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Phase 1 | X4 Pharmaceuticals | <1 mi |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | — | Prime Medicine, Inc. | <1 mi |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | <1 mi |
| A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems | Phase 1 | Boehringer Ingelheim | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | <1 mi |
| Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | Phase 2 | The University of Texas Health Science Center at San Antonio | <1 mi |
| Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma | — | The University of Texas Health Science Center at San Antonio | <1 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | <1 mi |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| Multi-analyte Blood Test Clinical Trial | — | Helio Genomics | <1 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | <1 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Phase 2 | Intercept Pharmaceuticals | <1 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | <1 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Phase 1 | Pilatus Biosciences Inc | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | <1 mi |
| Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| NAFLD Clinical Care Pathway | N/A | VA Office of Research and Development | <1 mi |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| High Dose Albumin in Refractory Ascites | Phase 2 | Baylor College of Medicine | <1 mi |
| Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis | Phase 1/2 | Prasun Kumar Jalal | <1 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | <1 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | <1 mi |
| Liver Disease in Urea Cycle Disorders | — | Baylor College of Medicine | <1 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | <1 mi |
| Natural History of Wilson Disease | — | Yale University | <1 mi |
| Hepatic Histopathology in Urea Cycle Disorders | — | Baylor College of Medicine | <1 mi |
| Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes | Phase 2 | LyGenesis, Inc. | <1 mi |
| The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | <1 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | <1 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response | N/A | M.D. Anderson Cancer Center | <1 mi |
| Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | Phase 1 | Shanghai Henlius Biotech | <1 mi |
| Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Phase 2 | Allison O'Neill, MD | <1 mi |
| Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | Phase 1 | Baylor College of Medicine | <1 mi |
| High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | N/A | M.D. Anderson Cancer Center | <1 mi |
| Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Phase 1/2 | 7 Hills Pharma, LLC | <1 mi |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study | — | UMC Utrecht | <1 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention | — | M.D. Anderson Cancer Center | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | <1 mi |
| A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | <1 mi |
| Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | <1 mi |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Phase 1/2 | Abivax S.A. | <1 mi |
| Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines | — | M.D. Anderson Cancer Center | <1 mi |
| Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Phase 4 | The Methodist Hospital Research Institute | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation | — | University of Alberta | <1 mi |
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk | Phase 2 | Raymond Chung | <1 mi |
| A-LiNK: Improving Outcomes in Autoimmune Liver Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| The Hepatitis C Transplant Collaborative | — | Baylor Research Institute | <1 mi |
| Non-Invasive Quantification of Liver Health in NASH (N-QUAN) | N/A | Perspectum | <1 mi |
| Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population | — | Methodist Health System | <1 mi |
| A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center | — | Methodist Health System | <1 mi |
| Functional Assessment in Liver Transplantation | — | University of California, San Francisco | <1 mi |
| Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial | Phase 2 | Samer Gawrieh | <1 mi |
| Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement | N/A | Methodist Health System | <1 mi |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Phase 3 | Bausch Health Americas, Inc. | <1 mi |
| Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) | Phase 4 | Camille N. Kotton, MD | <1 mi |
| T-Cell Therapy (ECT204) in Adults With Advanced HCC | Phase 1/2 | Eureka Therapeutics Inc. | <1 mi |
| EGCG for Hepatocellular Carcinoma Chemoprevention | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | — | National Cancer Institute (NCI) | <1 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | <1 mi |
| CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Evaluation of Resection Techniques for Pancreatic Tumors | — | Methodist Health System | <1 mi |
| A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | <1 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | <1 mi |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 2/3 | AbbVie | <1 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | <1 mi |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Phase 3 | Can-Fite BioPharma | <1 mi |
| Ligufalimab and Cadonilimab in Advanced Liver Cancers | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Phase 3 | Mirum Pharmaceuticals, Inc. | 12 mi |
| A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Phase 1 | Krystal Biotech, Inc. | 28 mi |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Alnylam Pharmaceuticals | 47 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | 47 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | 47 mi |